Shield Therapeutics promotes CFO to CEO as founder departs
Current CFO Tim Watts will replace outgoing CEO and company founder Carl Sterritt
Company
Shield Therapeutics PLC
LON:STX
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer ® /Feraccru ® (ferric maltol). The group has launched Accrufer® in the US and Feraccru ® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical for the development and commercialization of Accrufer ® / Feraccru ® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co in the Republic of Korea, and with KYE Pharmaceuticals in Canada.
175 stories · page 6 of 9
Shield Therapeutics carries out analysis on trial dataset
The company stressed that this clarification process will have no impact on either the existing marketing authorisations or prescribing information used in the regulatory submissions that led to the approval of its product in Europe, the US
Shield Therapeutics salutes year of material progress
Two key successes were the positive results of the AEGIS-H2H study (Ferracru vs Ferinject) and the FDA's approval of Accrufer
Shield Therapeutics ties up US$63mln deal for Feraccru in China
House broker finncap said it was a good deal especially considering that ASK has to fund a clinical trial in China.
Shield Therapeutics adopts Quoted Companies Alliance Corporate Governance Code
The QCA champions the interests of the 1,250 small- and medium-sized listed firms in the UK
Proactive snapshot: Collagen, Haydale Graphene, Arecor
A look at some of the top stories from the Proactive newswire on Tuesday
Shield Therapeutics to present phase IIIb study data to key opinion leaders
Principal investigator Dr Stefanie Howaldt, from the MVZ-Immunology Clinic in Hamburg, said: "This data shows that not only is Feraccru a real oral alternative to IV iron for these patients with iron deficiency anaemia, but that it can also
Shield Therapeutics hopes to have US commercial partner by the year-end; gaining traction for key product in Europe
The updates were provided alongside the company's interim results
Archive
Proactive news snapshot: Shield Therapeutics, Block Energy, AFC Energy...
A glance at some of the day's highlights from the Proactive Investors newswire
Shield Therapeutics adds two-thirds to its value after receiving US approval for flagship product
The Food & Drug Administration has given what’s called broad label approval to Feraccru, which will be marketed as Accrufer in America
Archive
FTSE 100 closes near flat as global markets appear uninspired
Footsie closed up nearly a point at 7,368, while mid-cap cousin FTSE 250 shed over 77 points at 19,172
Archive
Tesco’s first quarter set to face tough comparisons
Tesco, DS Smith and PZ Cussons are the standout names in Thursday's diary.
Archive
Proactive news snapshot: Argo Blockchain, Sareum Holdings, WideCells Group …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
EQTEC gives ground as it draws on its loan facility
A look at the day's major movers, including Carclo, Sareum, Karelian, Kier, Fulcrum, Microsaic, Dignity and Scapa
Shield Therapeutics to continue “robust” defence of IP as Teva appeals Feraccru ruling
The pharmaceutical firm said no date for the appeal hearing had yet been set but it believed the initial EPO decision in its favour would be upheld
Shield Therapeutics primed for a busy year
Here we take a look under the hood of Shield Therapeutics
Archive
Gresham shoots higher as contract wins make for “excellent start” to the year
A look at some of the biggest risers and fallers in London on Thursday
Archive
Proactive news snapshot: Haydale Graphene, Echo Energy, ValiRx, Personal Group …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Westminster Group, Tekcapital, Shield Therapeutics …
A glance at some of the day's highlights from the Proactive Investors newswire